Health Insurance Status Affects Staging and Influences Treatment Strategies in Patients with Hepatocellular Carcinoma
- 162 Downloads
Lack of health insurance is associated with poorer outcomes for patients with cancers amenable to early detection. The effect of insurance status on hepatocellular carcinoma (HCC) presentation stage and treatment outcomes has not been examined. We examined the effect of health insurance status on stage of presentation, treatment strategies, and survival in patients with HCC.
The Tennessee Cancer Registry was queried for patients treated for HCC between January 2004 and December 2006. Patients were stratified by insurance status: (1) private insurance; (2) government insurance (non-Medicaid); (3) Medicaid; (4) uninsured. Logistic, Kaplan–Meier, and Cox models tested the effects of demographic and clinical covariates on the likelihood of having surgical or chemotherapeutic treatments and survival.
We identified 680 patients (208 private, 356 government, 75 Medicaid, 41 uninsured). Uninsured patients were more likely to be men, African American, and reside in an urban area (all P < 0.05). The uninsured were more likely to present with stage IV disease (P = 0.005). After adjusting for demographics and tumor stage, Medicaid and uninsured patients were less likely to receive surgical treatment (both P < 0.01) but were just as likely to be treated with chemotherapy (P ≥ 0.243). Survival was significantly better in privately insured patients and in those treated with surgery or chemotherapy (all P < 0.01). Demographic adjusted risk of death was doubled in the uninsured (P = 0.005).
Uninsured patients with HCC are more likely to present with late-stage disease. Although insurance status did not affect chemotherapy utilization, Medicaid and uninsured patients were less likely to receive surgical treatment.
Supported in part by the institutional National Research Service Award T32 HS 013833 (VZ) from the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.
- 9.Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–30.Google Scholar
- 15.Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.Google Scholar
- 16.United States Department of Agriculture. Economic Research Service. Rural-Urban Continuum Codes. http://www.ers.usda.gov/Data/RuralUrbanContinuumCodes/. Accessed February 2009.
- 17.Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer: Cancer Staging Manual. Liver (including intrahepatic bile ducts), 6th ed. New York, NY: Springer; 2002.Google Scholar
- 18.Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9(2):191–211, v.Google Scholar
- 29.Committee on the Consequences of Uninsurance BoHCS, Institute of Medicine. Care Without Coverage: Too Little; Too Late. Washington, DC: National Academy Press; 2002.Google Scholar